1 not yet recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Bi Nan: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC Durvalumab - Non-small Cell Lung Cancer Stage III, Borderline Resectable Carcinoma | Phase 2 | Not yet recruiting | Bi Nan | 80 | 2025-07-01 | 2025-05-31 |
Carcinoma, Non-Small-Cell Lung (1)
Chemoradiotherapy (1) · Surgical Procedures, Operative (1) · durvalumab (1)
China (1)
Jie He, MD (1)